Efficacy and Safety of Echinacoside in a Rat Osteopenia Model
Table 1
Serum parameters after 12-week administration of ECH.
Group
SHAM
OVX
E2
ECH-L
ECH-M
ECH-H
ALP (U/100 mL)
10.96 ± 1.36
14.76 ± 2.86##
11.66 ± 1.88*
12.20 ± 1.22*
12.00 ± 1.56*
10.95 ± 1.97**
TRACP-5b (U/L)
0.306 ± 0.026
0.367 ± 0.054#
0.294 ± 0.054*
0.277 ± 0.084*
0.231 ± 0.088**
0.227 ± 0.082**
OPG (pg/mL)
610.32 ± 85.29
516.36 ± 65.35#
621.41 ± 121.78*
631.77 ± 131.64*
729.42 ± 122.59**
775.29 ± 179.87**
RANKL (pg/mL)
6.44 ± 0.55
7.38 ± 0.83#
7.19 ± 1.75
6.38 ± 0.58*
6.15 ± 1.01*
5.75 ± 1.21**
OPG/RANKL ratio
95.09 ± 13.44
70.32 ± 8.53##
92.74 ± 35.72
100.75 ± 28.50*
121.41 ± 29.23**
138.98 ± 39.16**
The data are expressed as mean ± SD, n = 8. #P < 0.05 and ##P < 0.01 versus SHAM group, *P < 0.05 and **P < 0.01 versus OVX group at the same time point as evaluated by ANOVA.
